The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00592618
Verified May 2007 by Assaf-Harofeh Medical Center. Recruitment status was: Not yet recruiting
Sleep studies in ESRD patients have identified increased prevalence of Sleep Apnea. Based on current knowledge, treatment aimed at reducing oxidative stress might improve Sleep Apnea in HD patients. The aim of our study is to investigate the effect of N-acetylsysteine on Sleep Apnea in HD patients.
Condition or disease
Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:
The study will include 20 patients with ESRD, treated with chronic hemodialysis in Assaf Harofeh Medical Center and suffering from sleep disturbances, such as frequent arousals, snoring, daytime sleepiness.
Patients will be excluded from the study if they are:
Recently started treated with chronic dialysis: less than 3 months.
Survived recent major illness, requiring hospitalisation in the last 3 months.
Patients with acute renal failure
Currently treated with antioxidants ( NAC, vitamin E ets.)